Multi-Center Trial Shows Significant Pain Relief For Spine Cancer Patients Following Targeted Radiofrequency Ablation Treatment

Treatment of Metastatic Posterior Vertebral Body Osseous Tumors by Using a Targeted Bipolar Radiofrequency Ablation Device: Technical Note

ReSolve® Biliary Locking Drainage Catheter Receives CE Mark!


I am pleased to announce that the ReSolve® Biliary Locking Drainage Catheter has received the CE mark and is available for sale in Europe.

These catheters are indicated for drainage of bile within the biliary system. Often biliary systems need to be decompressed due to bile duct stones, extrahepatic, or intrahepatic tumors, and primary sclerosing cholangitis, among other reasons. In addition bile may also need to be diverted from a bile duct leak.

Biliary system lesions do not always occur in the same location in every patient. Because of this, Merit offers catheters with two different drainage hole configurations to accommodate patient anatomy and multiple disease locations.

Correct catheter positioning is important in these procedures. The catheter features a radiopaque marker band near the proximal shaft drainage hole, and non-radiopaque depth markers the entire length of the catheter to help with fast and accurate positioning.

Additional features:

  • Atraumatic pigtail
  • Smooth transitions
  • Large drainage holes
  • Hydrophilic coating
  • Kink resistance

To learn more, check out the  ReSolve® Biliary Locking Drainage Catheter product webpage.

Richard Collard
Senior Product Manager
Merit Medical Systems, Inc.

DFINE Announces Commencement Of Clinical Study On Spinal Tumor Ablation With The STAR Tumor Ablation System

Safeguard® and Ergonomics in the Cath Lab

I recently read an article by Marsha Holton, CCRN, RCIS, FSICP, “An Ergonomic Survey of Cath Lab Repetitive Stress Injuries,” who observed that the duration of manual compression may be one of the ergonomic risk factors for cath lab repetitive stress injuries.

“Survey results regarding recovering access sites were surprising, particularly the mean holding pressure time of 19 minutes*. We may have identified at least one task that could increase the risk of carpal tunnel injury to our health care workers. Three of the seven ergonomic risks are involved in holding manual pressure. These are the risks of position and pressure, force, and duration, which may explain the trembling of those hands that held for 19 minutes.” [* Emphasis added]

As a result of her survey, Ms. Holton encourages cath lab professionals to look for ways to reduce the risk of injury.

“If there is even a possibility that such injuries are caused by our work, it is important to identify what is hurting cath lab professionals, and what we can do to decrease the number of future injuries.”

For those who are looking for ways to reduce the duration of manual compression, I recommend using the Safeguard Pressure Assisted device. The Safeguard Manual Assist (SMAT) study—a multicenter trial of over 100 patients found that the device was effective in reducing active compression time.

  • The mean active compression time for all patients (n = 100): 7.7±3.3 minutes
  • The mean active compression time for diagnostic patients (n = 72): 6.6±2.9 minutes
  • The mean active compression time for interventional patients (n = 28): 10.5±2.5 minutes

Safeguard is indicated in the reduction of active compression time in femoral artery cannulation following diagnostic and interventional procedures and it is effective in obtaining and maintaining hemostasis. It has a clear polyurethane window and bladder with adhesive backing and a Luer valve for inflation with a syringe to provide pressure to the puncture site.

Testimonials from two of the nurses who participated in the SMAT study support the effectiveness and comfort of the device:

“Well, I love this product because my hand doesn’t hurt when I go home at night.” —Karen Cronin, RN

“Safeguard is just a great thing for nurses and a great thing for the patients.” —Judy Champion, RN

To learn more about the Safeguard Manual Assist Technique, contact your local Merit Medical Sales Representative.

Mark Heninger
Senior Product Manager

Merit Medical Offers PD Kit for Interventional Radiologists

Introducing the NEW Merit Percutaneous Implantation Kit for peritoneal dialysis (PD) catheter placement. The kit is designed to accommodate stylette or over-the-wire placement using ultrasound guided access and fluoroscopy. At the recent Society of Interventional Radiology (SIR) meeting in San Diego, physicians were thrilled to learn about this procedure and the advantages of the Merit percutaneous kit over the competitor’s kit. This percutaneous kit is unique because it has a number of components not currently offered in competitive kits. These unique features include:

  • 18G echogenic needle
  • Two Dilators: 12F and 14F for serial dilation
  • Cuff Implantor: Designed to simplify implanting the cuff through a smaller incision
  • 0.038″ x 150 cm Wire: Long enough to place the catheter over the wire
  • Tunneler: Specifically designed to match the O.D. of our catheter and sized for a small, tight exit site

Each Merit PD catheter, sold separately from the implantation kit, includes a sterile implantation stencil to promote placement accuracy and better PD catheter outcomes.

Product configurations: VP-511 (Includes plastic Faller Trocar) and VP-511M (Includes metal Faller Trocar)

In addition to these kits, Merit offers a number of interventional tools to assist in these procedures such as the Merit Laureate® hydrophilic guide wire and MAK-NV™ non-vascular micro puncture sets.

To learn more about these kits, visit our PD product web page or contact your local Merit Sales Representative.

Lynette Ruppel
Senior Product Manager

The Importance of Having Options for Foreign Body Manipulation and Retrieval

A survey conducted by Merit Medical found that radiologists, cardiologists, and vascular surgeons use, on average, two or more different endovascular snare devices in their practice. These physicians understand the importance of having options when a foreign object such as an IVC filter, stent, balloon fragment, broken catheter tip, or guide wire tip needs to be retrieved from the vasculature.

EN Snare® Endovascular Snare System and ONE Snare® Endovascular Snare System

Merit Medical recognizes this need and is pleased to be the only provider of two snare systems: an interlaced triple loop device–the EN Snare® Endovascular Snare System, and a single loop snare device–the ONE Snare® Endovascular Snare System. The EN Snare® and the ONE Snare® go hand-in-hand to provide physicians with the necessary options they need to meet any clinically-challenging case that may arise.

Check out our website to learn more about the suite of Merit Endovascular Snare Systems.

Jesse Hansen
Director of Marketing – Interventional Radiology

Retrospective Analysis Study Shows CentrosFLO® Long-Term Hemodialysis Catheter Tip Design Offers Greater Patency


The Merit Medical CentrosFLO long-term hemodialysis catheter’s self-centering split-tip design has a greater separation between the arterial and venous tips than the symmetric-tip designed catheter. Its design is intended to optimize catheter patency and reduce fibrin sheath formation, thrombosis and vessel wall occlusions by keeping the tips of the catheter centered in the vessel and away from the vessel wall.

In May of 2013, a retrospective study was completed by Dr. Saravanan Balamuthusamy (“Dr. Bala”) at Angiocare, Vascular and Interventional Nephrology, in Tucson, Arizona. The performance and safety of a new self-centering, split tip hemodialysis tunneled catheter was compared with a symmetric-tip catheter in 58 patients.

Study Conclusion1
The study results indicated that the CentrosFLO self-centering, split-tip catheter had statistically greater patency after 3 months with similar clearance and blood flow.

Split-Tip Design
(n = 38)
(n = 20)
Patency94.7%75.0%P = 0.04
Mean Clearance (Kt/V)21.4831.423NSD4 (p = 0.48)
Mean Blood Flow (ml/min)2393.93381.63NSD4 (p = 0.27)

1 Study data on file.
2 Mean value during the three-month follow-up period.
3 Mean clearance and mean blood flow did not include data from patients with no catheter patency.
4 NSD = Not Statistically Significant, p > 0.05 (t-tests).

For a full published version of this study, contact your local Merit Sales Representative.

Nate Smith – Senior Product Manager
Merit Medical Systems, Inc.

New! 7.5F ReSolve® Locking and Non-Locking Drainage Catheter

We are now pleased to offer the ReSolve® Locking and Non-Locking Drainage Catheters in 7.5F. These catheters are indicated for percutaneous drainage of fluid from body cavities. Some of the drainage procedures performed with these catheters are abscess, nephrostomy and cyst.

For many fluid collections, a 6.5F catheter is often too small to drain the fluid, but an 8.5F catheter is too large for the patient. These new catheters are great for those fluid collections and patients where an in-between catheter is needed.

These catheters continue to offer

  • Smooth transitions
  • Large drainage holes
  • Hydrophilic coating
  • Kink resistance

For more product information on Merit’s Drainage Products, visit

Uterine Fibroid Embolization

Ask4UFE Website Revamped

ask4UFE uterine fibroids education campaign websiteFor more than a decade, the Ask4UFE patient education campaign has been an invaluable resource for the many women who suffer from symptomatic uterine fibroids. Our campaign has educated hundreds of women and empowered them to become more involved in the decision-making process for treating uterine fibroids. Our campaign provides women who suffer from fibroids with information on all the available treatment options.

We are more impassioned than ever to help raise the awareness level around fibroids and all available treatment options. The revamp of our website,, is a huge milestone for us and represents the rebirth of our awareness campaign.

Help us raise the awareness level about uterine fibroids and don’t forget to Ask4UFE!

Your friends at Ask4UFE

Merit Medical’s Safeguard® Allows Parents to Hold Their Babies After Heart Surgery

I have a grandson that is 20 months old and who is in perpetual motion. If he’s awake, his inquiring mind has him looking, touching and listening to everything. Recently he injured his hand, pinching it in a door. It wasn’t serious, but all of a sudden he went from running around his playroom, to wanting to be held by his mother. It was as if it didn’t hurt if she was holding him.

In reflecting on this, I think of children who undergo a diagnostic or interventional cardiology procedure in the Pediatric Cath Lab, such as septal defects (ASDs or VSDs) or valve defects, such as pulmonary valve stenosis, among others. When the procedure is finished and they are in recovery, these young patients have the same desire to be held that my grandson exhibited. Merit Medical’s Safeguard Pressure Assisted Device gives children the ability to be held by their parents after heart surgery.

In an article in the November 2006 issue of Cath Lab Digest, Jill Dykstra, RN and Kathy Laird, RN with the Congenital Heart Institute at the Arnold Palmer Hospital for Children, in Orlando, Florida authored an article titled, Use of the Safeguard Pressure-Assisted Dressing for Patients Less than 15 kg Following Cardiac Catheterization. In it they stated: “…Prior to implementation of the Safeguard hemostasis device, methods for maintaining hemostasis included pressure dressings that did not allow for the parents to hold the infant…”

This 6-month study found that “…the Safeguard device does not restrict mobility and allows for parental contact immediately post-procedure.

The Safeguard gives clinical personnel a pressure assisted device that promotes hemostasis, decreases occurrences of re-bleeds, and most important, gives a child the comfort of being in the arms of a parent.

For more information regarding Safeguard and Merit’s comprehensive line of products for promoting hemostasis, visit

Mark Heninger
Senior Product Manager

Merit Medical Opens Office in Bangalore, India

Merit Medical Systems is expanding with a new office in Bangalore, India.


This new location will allow Merit to take advantage of the growing Indian healthcare market.
The key reason for opening an office to serve the Indian market is the large need that has been generated for our products over the last 3-5 years.

image2-18Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional and diagnostic procedures in several disciplines including cardiology, radiology, nephrology, vascular surgery, electrophysiology, and endoscopy. Merit Medical has several therapeutic products to help clinicians treat patients suffering from uterine fibroids, tumors, end stage renal disease, strictures of the airway, and blood clots. Our therapeutic products include devices and accessories used to support the implantation of pacemakers and the treatment of irregular heartbeats.

Merit Medical Systems India Pvt Ltd is located at the following address:
206-207, HM Geneva House
14 Cunningham Road
Bangalore- 560052, INDIA
Phone: +91-80-41223378
Fax: 91-80-41223365

The office will be used for sales and marketing operations in the region.

Merit Medical EP Group Announces Launch of HeartSpan® Steerable Sheath Introducer

Merit Medical continues to add to its extensive line of products for Electrophysiology. The HeartSpan Steerable Sheath Introducer offers control, coverage and comfort for Electrophysiologists when navigating cardiac chambers. The 8.5F HeartSpan Steerable Sheath Introducer’s braided construction provides kink resistance and curve durability. The distal tapered tip creates a smooth transition from the dilator to sheath introducer to reduce trauma to the atrial septum.


  • Softer, flexible tip
  • Smooth transition from dilator
  • Responsive curve deflection
  • Braided construction for kink resistance


  • Bidirectional (180-degree) deflection
  • Small curl (16.4 mm)
  • Medium curl (22.4 mm)
  • Large curl (36.0 mm)


  • Ergonomic shape
  • Improved grip size

The HeartSpan line of products also includes the HeartSpan® Fixed Curve Braided Transseptal Sheath with braided steel shaft for excellent torqueability and the HeartSpan® Transseptal Needle designed to be exceptionally responsive with enhanced stiffness.

Our EP team is excited to introduce this new steerable sheath designed to help EPs extend their options.

Merit Medical’s ConcierGE® Has Better Kink Resistance and 1:1 Torque Than Leading Guiding Catheter Brands

THE BAR HAS BEEN RAISED by Merit Medical with the introduction of the Merit ConcierGE Guiding Excellence Catheter.

In an independent survey, approximately 40% on Interventional Cardiologists indicated that their current guiding catheter does not meet their needs for kink resistance.

Designed in 5F, 6F, 7F, and 8F, ConcierGE is the first guiding catheter designed with a higher level of guiding excellence.

Kink Resistance
The ConcierGE has approximately
30% more kink resistance*
than the leading brands, facilitating
the advancement and withdrawal of
interventional devices.
1:1 Torque
The ConcierGE test results prove
that it has better 1:1 torque
response** than the leading
brands, promoting quicker catheter
seating with less whipping.*

Each feature of the guiding catheter is designed to give you added confidence in difficult cases by optimizing clinical benefits without compromise during coronary angioplasty.

To learn more about how Merit has raised the bar for guiding catheter performance, read the ConcierGE Brochure or watch the ConcierGE Guiding Catheter product video.

Tami Anderson,
Senior Product Manager

New Studies Highlight Benefits Of STAR Tumor Ablation System For Patients With Spinal Tumors

San Jose, Calif. – Feb. 18, 2014 –Two studies presented at the American Society of Spine Radiology (ASSR) 2014 Annual Symposium in Miami highlighted the benefits of Targeted Radiofrequency Ablation™ (t-RFA) therapy with the DFINE STAR™ Tumor Ablation System. The studies demonstrated the ability of the STAR System to provide significant pain relief to patients suffering from painful spinal metatases; in many cases, these patients had not responded to standard therapies, such as radiation or chemotherapy. The first study, conducted by Bassem Georgy, M.D., Assistant Clinical Professor of Radiology at the University of California, San Diego, noted improvement in pain and functional status (quality of life) in all patients. The study also concluded that the targeted and minimally invasive nature of the STAR System allowed treatment of all of the studied tumors regardless of their location. The second study, conducted by Jack Jennings, M.D., PhD, Director of Musculoskeletal and Spine Interventions at the Mallinckrodt Institute of Radiology in St. Louis, demonstrated the value of the STAR System in treating patients who were not responsive to other standard treatments and who had tumors very close to the spinal cord (posterior lesions). In addition to relieving pain, the study concluded that the STAR System had successfully destroyed the lesions, and that in many patients no regrowth was observed during the study period.< “We are pleased with the continued success of STAR in providing pain relief to the many cancer patients suffering from spinal tumors,” said Greg Barrett, Chief Executive Officer of DFINE. “The therapy continues to gain momentum and we are gratified to see more clinicians embracing the technology to help their patients.” About STAR™ Tumor Ablation System The STAR Tumor Ablation System does not treat cancer. It was cleared by the FDA in 2010 for providing palliative treatment (e.g., pain relief) by ablation of metastatic malignant tumors in a vertebral body. With its use of targeted radiofrequency (RF) energy, the STAR System enables physicians to achieve pain relief through the use of a single, minimally invasive procedure that may be compatible with both chemo and radiation therapy. As with all surgical procedures, there are risks and contraindications associated with the STAR System which are described in the product labeling.  The STAR System is available at more than 200 institutions in the U.S. For more information regarding spinal tumors or to find a physician, visit About STAR™ Tumor Ablation System t-RFA with the STAR System does not treat cancer. It is cleared by the FDA for providing palliative treatment (e.g. pain relief) by ablation of metastatic malignant tumors in a vertebral body. For a complete list of indications, risks and contraindications, visit—SpineSTAR About DFINE, Inc.DFINE is dedicated to relieving pain and improving the quality of life for patients suffering from spinal diseases through innovative, minimally invasive therapies. The company’s flagship products, the StabiliT® Vertebral Augmentation System and STAR™ Tumor Ablation System, represent generational advancements in the minimally invasive treatment of spinal diseases. DFINE is based in San Jose, Calif. and is a privately held company. DFINE and StabiliT are registered trademarks and STAR and Targeted Radiofrequency Ablation (t-RFA) are trademarks of DFINE, Inc. Media Contact Susan Benton Russell T: 310-697-3488 [email protected]

Merit Medical Supports Utah’s “STEM Curiosity Unleashed” Campaign to Promote Science, Technology, Engineering and Math Education

Merit Medical joined Governor Gary Herbert and other business leaders at a recent news conference to kick off the State’s “STEM Curiosity Unleashed” campaign.


Merit and other Utah businesses donated $2.5 million dollars for an advertising campaign to encourage students to study and pursue careers in science, technology, engineering, and math.

The future of companies like Merit Medical depends on more people having a better understanding of science, technology, engineering and mathematics. We support STEM education because the future of our country depends upon it.

We are proud to participate in this effort to educate young people on the value of STEM education and the bright future that STEM careers offer.


Merit Laureate Hydrophilic Guide Wire

Merit Laureate® Hydrophilic Guide Wire Available In New 0.018″ Diameter




I’m pleased to announce that Merit will be offering a 0.018″ diameter Merit Laureate Hydrophilic Guide Wire worldwide effective February 3, 2014. Smaller diameter guide wires are used in a number of different applications including standard arterial and venous angiography, PTA of chronic total occlusions, thrombolytic therapy, vena cava grams, and endovenous laser ablations.
The Merit Laureate is Merit Medical’s premier hydrophilic guide wire for the placement of devices during diagnostic and interventional procedures in radiology, cardiology, vascular surgery, nephrology, and urology.


  • True 1:1 torque control for greater turn-for-turn responsiveness and rapid vessel selection
  • Reliable and lasting lubricity to minimize surface friction for navigating highly tortuous anatomy and rapid catheter exchanges
  • Enhanced lesion crossability
  • Dependable visualization under fluoroscopy

Available now in 0.018″, 0.025″, 0.035″, and 0.038″ diameters, 80 cm to 260 cm lengths, standard and stiff body, with angled and straight tip configurations. Click here to watch our Merit Laureate Product Demonstration Video with side- by-side comparison to the market leader and a product feature animation.

Senior Product Manager

Merit Medical Receives 510(k) Clearance for ASAPLP™ Low Profile Aspiration Catheter

I’m pleased to announce that we have received 510(k) clearance for the ASAPLP Low Profile Aspiration Catheter, a new low-profile addition to our ASAP® line of aspiration catheters. The ASAPLP received the CE mark on August 30.


The ASAPLP is designed to remove fresh, soft emboli and thrombi from vessels of the arterial system.


  • Fits into 6F guide catheter of ≥0.066” with ease
  • A 4F catheter designed for maximum aspiration
  • Long 30 cm hydrophilic coating promoting deliverability
  • Longer 20 cm rapid exchange lumen designed for better wire trackability


  • 100% stainless steel braided, kink resistant 145 cm low profile aspiration catheter
  • Improved tip radiopacity due to radiopaque platinum iridium marker band
  • Bright colored wire exchange lumen


  • Packaged with stiffening stylet

ASAPLP is Merit Medical’s latest innovation for quick, effective aspiration! For more information on the ASAP line of aspiration catheters, see the the Aspiration Catheter Family Brochure.

Elizabeth Pratt
Senior Product Manager

ask 4 UFE - Uterine Fibroid Embolization

Cynthia Bailey, The Real Housewives of Atlanta Cast Member, Will Undergo Uterine Fibroid Embolization on November 17 Episode

Cynthia Bailey revealed that she had fibroids in last week’s episode of the Real Housewives of Atlanta. Cynthia complained of heavy bleeding and long menstrual periods and the toll it was taking on her body and her personal life.

On the episode, set to air on Sunday, November 17 at 8 PM Eastern time, the cameras will be present when Cynthia undergoes a uterine fibroid embolization (UFE) procedure. Cynthia described the results of her UFE procedure in a recent interview as “life changing.” “Everything has changed and it has been amazing. I’m so glad I took care of it.” She said that she decided to share this experience to promote public awareness of uterine fibroids.

Uterine fibroids affect millions of women between the ages of 20 and 50 and are more common in African American women. Bailey hopes that fans will be inspired by her story.

Merit Medical sponsors an informational resource, the website, devoted to educating women about fibroids, treatment options, and UFE. The website includes a Physician Locator Tool to help women find physicians in their area who perform the UFE procedure.

ask4ufe logo

Merit Medical also offers embolization products that are used in uterine fibroid embolization (UFE) procedures: Embosphere® Microspheres and Bearing nsPVA™ nonspherical polyvinyl alcohol embolization particles. UFE is a less invasive treatment than hysterectomy. Go to today to determine if UFE is the right treatment option for you.

Comparison of Radiofrequency-targeted Vertebral Augmentation with Balloon Kyphoplasty for the Treatment of Vertebral Compression Fractures: 2-year Results.